{"id":32769,"date":"2026-02-09T09:06:08","date_gmt":"2026-02-09T09:06:08","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/medical-writing-market-mordor\/"},"modified":"2026-09-11T17:18:23","modified_gmt":"2026-09-11T08:18:23","slug":"medical-writing-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/medical-writing-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \uc758\ud559 \uc791\ubb38 \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026-2031\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/medical-writing-market_1663227479490_Competitive_Landscape_and_Logo_Format.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/medical-writing-market-size-image-1767809825009.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">\n    1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">\n          1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          1.2 \uc5f0\uad6c \ubc94\uc704<\/p>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">\n    2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">\n    3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">\n    4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">\n          4.1 \uc2dc\uc7a5 \uac1c\uc694<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          4.2 \uc2dc\uc7a5 \ub3d9\uc778<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          4.2.1 \uc99d\uac00\ud558\ub294 R&amp;D \uc9c0\ucd9c \ubc0f \uc2e0\uaddc \uce58\ub8cc\uc81c \uac1c\ubc1c<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.2 CRO \uc544\uc6c3\uc18c\uc2f1 \ubaa8\ub378\uc758 \ud655\uc7a5<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.3 \uc99d\uac00\ud558\ub294 \uaddc\uc81c \ubcf5\uc7a1\uc131 \ubc0f \ubb38\uc11c\ub7c9<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.4 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ubc0f \ub9de\ucda4\ud615 \uc758\uc57d\ud488 \ucc44\ud0dd \uc99d\uac00<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.5 \uc804\ubb38\uac00 \uac10\ub3c5\uc774 \ud544\uc694\ud55c AI \uae30\ubc18 \ucf58\ud150\uce20 \uc790\ub3d9\ud654<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.6 \uc801\uc751\ud615 \ub2e4\uad6d\uc5b4 \ud504\ub85c\ud1a0\ucf5c\uc744 \uc8fc\ub3c4\ud558\ub294 \ubd84\uc0b0\ud615\/\uac00\uc0c1 \uc784\uc0c1\uc2dc\ud5d8<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          4.3 \uc2dc\uc7a5 \uc81c\uc57d<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          4.3.1 \uc219\ub828\ub41c \uc758\ub8cc \uc791\ubb38 \uc804\ubb38\uac00 \ubd80\uc871<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.3.2 \uc870\ub2ec \ud1b5\ud569\uc73c\ub85c \uc778\ud55c \uac00\uaca9 \uc555\ub825<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.3.3 \uc720\ub839 \uc791\ubb38 \ubc0f \uc800\uc790 \ud22c\uba85\uc131\uc5d0 \ub300\ud55c \uaddc\uc81c \uc870\uc0ac<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.3.4 \uc9c0\uc5ed\ubcc4 \uc81c\ucd9c \ud15c\ud50c\ub9bf\uc5d0 \ub300\ud55c \ub192\uc740 \uaddc\uc815 \uc900\uc218 \ube44\uc6a9<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          4.4 \uaddc\uc81c \ud658\uacbd<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          4.5 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778 \ubd84\uc11d<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          4.5.1 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.5.2 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.5.3 \uacf5\uae09\uc5c5\uccb4\uc758 \uad50\uc12d\ub825<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.5.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.5.5 \uacbd\uc7c1 \uac15\ub3c4<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">\n    5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (\uac00\uce58, USD)<\/p>\n<ul>\n<li class=\"toc-level-2\">\n          5.1 \uc720\ud615\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.1.1 \uaddc\uc81c \uc758\ub8cc \ubb38\uc11c \uc791\uc131<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.1.2 \uc784\uc0c1 \ubb38\uc11c \uc791\uc131<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.1.3 \uacfc\ud559 \ubc0f HEOR \ubb38\uc11c \uc791\uc131<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.1.4 \uae30\ud0c0<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          5.2 \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.2.1 \uc81c\uc57d \ud68c\uc0ac<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.2 \uc0dd\uba85\uacf5\ud559 \ud68c\uc0ac<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.3 \uacc4\uc57d \uc5f0\uad6c \uae30\uad00<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.4 \uc758\ub8cc \uae30\uae30 \uc81c\uc870\uc5c5\uccb4<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.5 \ud559\uc220 &amp; \uc5f0\uad6c \uae30\uad00<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.6 \uae30\ud0c0<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          5.3 \uce58\ub8cc \ubd84\uc57c\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.3.1 \uc885\uc591\ud559<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.3.2 \uc2ec\uc7a5\ud559<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.3.3 \uc911\ucd94\uc2e0\uacbd\uacc4 &amp; \uc2e0\uacbd\ud559<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.3.4 \uba74\uc5ed\ud559<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.3.5 \ud76c\uadc0 \uc9c8\ud658<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.3.6 \uae30\ud0c0<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          5.4 \uc9c0\uc5ed\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.4.1 \ubd81\ubbf8<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.1.1 \ubbf8\uad6d<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.1.2 \uce90\ub098\ub2e4<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.1.3 \uba55\uc2dc\ucf54<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.4.2 \uc720\ub7fd<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.2.1 \ub3c5\uc77c<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.2.2 \uc601\uad6d<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.2.3 \ud504\ub791\uc2a4<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.2.4 \uc774\ud0c8\ub9ac\uc544<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.2.5 \uc2a4\ud398\uc778<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.2.6 \uc720\ub7fd \uae30\ud0c0 \uc9c0\uc5ed<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.4.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.3.1 \uc911\uad6d<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.3.2 \uc77c\ubcf8<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.3.3 \uc778\ub3c4<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.3.4 \ud638\uc8fc<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.3.5 \ub300\ud55c\ubbfc\uad6d<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.3.6 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uae30\ud0c0 \uc9c0\uc5ed<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.4.4 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.4.1 GCC<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.4.3 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74 \uae30\ud0c0 \uc9c0\uc5ed<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.4.5 \ub0a8\ubbf8<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.5.1 \ube0c\ub77c\uc9c8<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.4.5.3 \ub0a8\ubbf8 \uae30\ud0c0 \uc9c0\uc5ed<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">\n    6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">\n          6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          6.3 \ud68c\uc0ac \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uac1c\uc694, \uc2dc\uc7a5 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc0ac\uc6a9 \uac00\ub2a5\ud55c \uc7ac\ubb34 \uc815\ubcf4, \uc804\ub7b5 \uc815\ubcf4, \uc8fc\uc694 \uae30\uc5c5\uc758 \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          6.3.1 IQVIA Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.2 ICON plc<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.3 LabCorp (Covance \ud3ec\ud568)<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.4 Parexel International<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.5 Cardinal Health<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.6 Certara USA Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.7 Freyr Solutions<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.8 InClin Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.9 Quanticate<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.10 Synchrogenix (Certara \uacc4\uc5f4\uc0ac)<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.11 Trilogy Writing &amp; Consulting GmbH<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.12 SIRO Clinpharm Pvt Ltd<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.13 OMICS International<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.14 Medpace Holdings Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.15 PPD Inc. (Thermo Fisher Scientific)<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.16 ProPharma Group<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.17 Cactus Communications<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.18 BioClinica (Clario)<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.19 ClinTec International<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.20 Kainos<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">\n    7. \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5 \uaddc\ubaa8, \ub3d9\ud5a5 \ubc0f \uc131\uc7a5 \ub3d9\uc778 2031\ub144\uae4c\uc9c0 \uc0c1\uc138 \ubd84\uc11d<\/p>\n<p># 1. \uc2dc\uc7a5 \uac1c\uc694 \ubc0f \uc804\ub9dd<\/p>\n<p>\uc758\ub8cc \ubb38\uc11c \uc791\uc131(Medical Writing) \uc2dc\uc7a5\uc740 2025\ub144 39\uc5b5 4\ucc9c\ub9cc \ub2ec\ub7ec\uc5d0\uc11c 2026\ub144 43\uc5b5 3\ucc9c\ub9cc \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 9.98%\ub97c \uae30\ub85d\ud558\uba70 2031\ub144\uc5d0\ub294 69\uc5b5 7\ucc9c\ub9cc \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc131\uc7a5\uc740 \uaddc\uc81c \uc9c0\uce68\uc758 \ube60\ub978 \uc5c5\ub370\uc774\ud2b8, \ucca8\ub2e8 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\uc758 \ubd80\uc0c1, \ubd84\uc0b0\ud615 \uc784\uc0c1\uc2dc\ud5d8\uc758 \uc99d\uac00\ub85c \uc778\ud55c \ubb38\uc11c\ud654 \uc791\uc5c5\ub7c9\uc758 \uae09\uc99d\uc5d0 \uae30\uc778\ud569\ub2c8\ub2e4. \uc2a4\ud3f0\uc11c\ub4e4\uc740 \uaddc\uc81c \uc804\ubb38\uc131\uc744 \uac16\ucd98 \uc804\ubb38 \ud30c\ud2b8\ub108\ub97c \uc801\uadf9\uc801\uc73c\ub85c \ucc3e\uace0 \uc788\uc73c\uba70, \uacc4\uc57d \uc5f0\uad6c \uae30\uad00(CRO) \uac04\uc758 \ud1b5\ud569\uc740 \uacbd\uc7c1 \uad6c\ub3c4\ub97c \uc7ac\ud3b8\ud558\uc5ec \ud1b5\ud569 \ud50c\ub7ab\ud3fc\uc774 \uac1c\ubc1c \uae30\uac04 \ub2e8\ucd95\uc5d0 \ub9de\ucdb0 \uc5d4\ub4dc-\ud22c-\uc5d4\ub4dc \uc9c0\uc6d0\uc744 \uc81c\uacf5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc9c0\uc5ed\ubcc4\ub85c\ub294 \ubd81\ubbf8\uac00 \uac00\uc7a5 \ud070 \uc2dc\uc7a5\uc744 \ucc28\uc9c0\ud558\uace0 \uc788\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \ub450 \uc790\ub9bf\uc218 \uc131\uc7a5\uc744 \uae30\ub85d\ud558\uba70 \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5\uc73c\ub85c \ubd80\uc0c1\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub294 \ub2e4\uad6d\uc5b4 \ud504\ub85c\ud1a0\ucf5c \uac1c\ubc1c \ubc0f \uc9c0\uc5ed\ubcc4 \uc81c\ucd9c \uc591\uc2dd\uc5d0 \ub300\ud55c \uc0b0\uc5c5\uc758 \uc804\ud658\uc744 \ubc18\uc601\ud569\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uc219\ub828\ub41c \uc791\uac00 \uc778\ub825 \ubd80\uc871\uc740 \uc5ec\uc804\ud788 \uc911\uc694\ud55c \ubcd1\ubaa9 \ud604\uc0c1\uc73c\ub85c \uc791\uc6a9\ud558\uc5ec \uc784\uae08 \uc778\ud50c\ub808\uc774\uc158\uc744 \ubd80\ucd94\uae30\uace0, \uc804\ubb38\uac00\uc758 \uac10\ub3c5\uc774 \ud544\uc694\ud55c \uc0dd\uc131\ud615 AI \uc194\ub8e8\uc158\uc758 \ub3c4\uc785\uc744 \ucd09\uc9c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc2dc\uc7a5 \uc9d1\uc911\ub3c4\ub294 \uc911\uac04 \uc218\uc900\uc73c\ub85c \ud3c9\uac00\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uc2dc\uc7a5 \uc9c0\ud45c (2026-2031):<br \/>\n*   \uc5f0\uad6c \uae30\uac04: 2020 &#8211; 2031\ub144<br \/>\n*   2026\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 43\uc5b5 3\ucc9c\ub9cc \ub2ec\ub7ec<br \/>\n*   2031\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 69\uc5b5 7\ucc9c\ub9cc \ub2ec\ub7ec<br \/>\n*   \uc131\uc7a5\ub960 (2026-2031): 9.98% CAGR<br \/>\n*   \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5: \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<br \/>\n*   \uac00\uc7a5 \ud070 \uc2dc\uc7a5: \ubd81\ubbf8<br \/>\n*   \uc2dc\uc7a5 \uc9d1\uc911\ub3c4: \uc911\uac04<\/p>\n<p># 2. \uc8fc\uc694 \ubcf4\uace0\uc11c \uc694\uc57d<\/p>\n<p>*   \uc720\ud615\ubcc4: \uaddc\uc81c \uc758\ub8cc \ubb38\uc11c \uc791\uc131(Regulatory Medical Writing)\uc774 2025\ub144 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 41.88%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uacfc\ud559 \ubc0f HEOR(Health Economics and Outcomes Research) \ubb38\uc11c \uc791\uc131\uc740 2031\ub144\uae4c\uc9c0 10.74%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: \uc81c\uc57d \ud68c\uc0ac(Pharmaceutical Companies)\uac00 2025\ub144 \uc2dc\uc7a5 \uaddc\ubaa8\uc758 49.20%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc0dd\uba85\uacf5\ud559 \ud68c\uc0ac(Biotechnology Companies)\ub294 2031\ub144\uae4c\uc9c0 10.6%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<br \/>\n*   \uce58\ub8cc \uc601\uc5ed\ubcc4: \uc885\uc591\ud559(Oncology)\uc774 2025\ub144 \ub9e4\ucd9c \uc810\uc720\uc728\uc758 36.18%\ub97c \uae30\ub85d\ud588\uc73c\uba70, \uba74\uc5ed\ud559(Immunology)\uc740 2031\ub144\uae4c\uc9c0 10.77%\uc758 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: \ubd81\ubbf8\uac00 2025\ub144 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5 \uaddc\ubaa8\uc758 39.75%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\uc740 2031\ub144\uae4c\uc9c0 10.82%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p># 3. \uae00\ub85c\ubc8c \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \ud1b5\ucc30\ub825<\/p>\n<p> 3.1. \uc2dc\uc7a5 \uc131\uc7a5 \ub3d9\uc778<\/p>\n<p>*   R&#038;D \uc9c0\ucd9c \uc99d\uac00 \ubc0f \uc2e0\uaddc \uce58\ub8cc\uc81c \uac1c\ubc1c (+2.1% CAGR \uc601\ud5a5): 2024\ub144 \uae00\ub85c\ubc8c \uc0dd\uba85 \uacfc\ud559 \ub9e4\ucd9c\uc740 \uc57d 1\uc870 9\ucc9c\uc5b5 \ub2ec\ub7ec\uc5d0 \ub2ec\ud588\uc73c\uba70, \uc774 \uc911 \uc81c\uc57d \ubd80\ubb38\uc774 \uc57d 70%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uc774\ub294 \uc5c4\uaca9\ud55c \ubb38\uc11c\ud654\uac00 \ud544\uc694\ud55c \uc5f0\uad6c \ud30c\uc774\ud504\ub77c\uc778\uc758 \ud655\ub300\ub85c \uc774\uc5b4\uc9d1\ub2c8\ub2e4. FDA\ub294 2024\ub144\uc5d0 50\uac1c\uc758 \uc2e0\uc57d\uc744 \uc2b9\uc778\ud588\uc73c\uba70 2025\ub144\uc5d0\ub294 \ucd5c\ub300 70\uac1c \uc2b9\uc778\uc744 \uc608\uc0c1\ud558\uace0 \uc788\uc5b4, \ubb38\uc11c \uc791\uc131 \uae30\uac04\uc774 \ub2e8\ucd95\ub418\uace0 \uc81c\ucd9c \uc11c\ub958\uc758 \ubc94\uc704\uac00 \ub113\uc5b4\uc9c0\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c\uc640 \uac19\uc740 \ucca8\ub2e8 \uce58\ub8cc\ubc95\uc740 \uad11\ubc94\uc704\ud55c \ud654\ud559, \uc81c\uc870 \ubc0f \uad00\ub9ac(CMC) \uc139\uc158\uacfc \uac15\ub825\ud55c \uc704\ud5d8-\uc774\uc810 \uc11c\uc220\uc744 \uc694\uad6c\ud569\ub2c8\ub2e4. \uc2b9\uc778 \ud6c4 \uc99d\uac70 \ud504\ub85c\uadf8\ub7a8\uc5d0 \ub300\ud55c \ud22c\uc790 \uc99d\uac00 \ub610\ud55c \ucd08\uae30 \ud5c8\uac00 \uc774\ud6c4\uc5d0\ub3c4 \ubb38\uc11c \uc791\uc131 \uc791\uc5c5\uc758 \uc218\uba85\uc744 \uc5f0\uc7a5\uc2dc\ud0a4\uba70, \uc774\ub7ec\ud55c \uc694\uc778\ub4e4\uc774 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5\uc5d0 \ud65c\ub825\uc744 \ubd88\uc5b4\ub123\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>*   CRO \uc544\uc6c3\uc18c\uc2f1 \ubaa8\ub378 \ud655\uc7a5 (+1.8% CAGR \uc601\ud5a5): \uc804 \uc138\uacc4 CRO \ubd80\ubb38\uc740 2024\ub144\uc5d0 \uc57d 820\uc5b5 \ub2ec\ub7ec\uc5d0 \ub2ec\ud588\uc73c\uba70, \uc774\ub294 \ube44\uc6a9 \ud6a8\uc728\uc131\uacfc \uc6b4\uc601 \ud1b5\uc81c\uc758 \uade0\ud615\uc744 \ub9de\ucd94\uae30 \uc704\ud574 \uae30\ub2a5 \uc11c\ube44\uc2a4 \uc81c\uacf5\uc790(FSP) \uacc4\uc57d\uc744 \uc120\ud638\ud558\ub294 \uc2a4\ud3f0\uc11c\ub4e4\uc5d0 \uc758\ud574 \uc8fc\ub3c4\ub418\uc5c8\uc2b5\ub2c8\ub2e4. 2024\ub144 3\uc6d4 Indegene\uc758 Trilogy Writing &#038; Consulting \uc778\uc218\uc640 \uac19\uc740 \ub300\uaddc\ubaa8 \uac70\ub798\ub294 \ud1b5\ud569 \ud50c\ub7ab\ud3fc\uc774 \uae00\ub85c\ubc8c \ud504\ub85c\uadf8\ub7a8\uc5d0 \ud544\uc694\ud55c \uc77c\uad00\ub41c \ubb38\uc11c\ud654 \uc9c0\uc6d0\uc744 \uc81c\uacf5\ud558\uae30 \uc704\ud574 \uc5ed\ub7c9\uc744 \uac15\ud654\ud558\uace0 \uc788\uc74c\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4. \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc5d0\uc11c\ub294 \uaddc\uc81c \uc2dc\uc2a4\ud15c\uc758 \ubc1c\uc804\uacfc \ube44\uc6a9 \uc774\uc810\uc73c\ub85c \uc778\ud574 \uc678\ubd80 \ud30c\ud2b8\ub108 \ucc44\ud0dd\uc774 \uac00\uc7a5 \ube60\ub974\uac8c \uc99d\uac00\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc720\uc5f0\ud55c FSP \uacc4\uc57d\uc744 \uc0ac\uc6a9\ud558\ub294 \uc2a4\ud3f0\uc11c\ub294 \ud30c\uc774\ud504\ub77c\uc778 \ubcc0\ub3d9\uc5d0 \ub9de\ucdb0 \uc791\uac00 \uc778\ub825\uc744 \ud655\uc7a5\ud558\uc5ec \uc608\uc0b0 \uc608\uce21 \uac00\ub2a5\uc131\uc744 \ub192\uc77c \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>*   \uaddc\uc81c \ubcf5\uc7a1\uc131 \ubc0f \ubb38\uc11c\ud654 \ubcfc\ub968 \uc99d\uac00 (+2.3% CAGR \uc601\ud5a5): 2024\ub144 FDA\ub294 \uc804\uc790 \uc81c\ucd9c, AI \uae30\ubc18 \uae30\uae30, \ubd84\uc0b0\ud615 \uc784\uc0c1\uc2dc\ud5d8 \uac10\ub3c5 \ub4f1 25\uac1c \uc774\uc0c1\uc758 \uc0c8\ub85c\uc6b4 \uc9c0\uce68 \ubb38\uc11c\ub97c \ubc1c\ud45c\ud558\uc5ec \uc804\uccb4 \ubb38\uc11c \uc791\uc131 \uc791\uc5c5\ub7c9\uc744 25-30% \uc99d\uac00\uc2dc\ucf30\uc2b5\ub2c8\ub2e4. eCTD v4.0\uc73c\ub85c\uc758 \uc804\ud658\uacfc \uac15\ud654\ub41c \ubaa8\ub4c8 1 \uc694\uad6c\uc0ac\ud56d\uc740 \uc9c0\uc5ed \uac04 \uc870\ud654\uc5d0 \ub300\ud55c \uc694\uad6c\ub97c \ub192\uc785\ub2c8\ub2e4. \uc911\uad6d\uc758 24\uac1c \uac1c\ud601 \ub85c\ub4dc\ub9f5\uc740 2027\ub144\uae4c\uc9c0 \uc804\uba74 \uc2dc\ud589\ub420 \uc608\uc815\uc774\uba70, \uc2a4\ud3f0\uc11c\ub4e4\uc740 \uc0c8\ub85c\uc6b4 \ud22c\uba85\uc131 \ud45c\uc900\uc744 \ud1b5\ud569\ud55c \uc911\uad6d\uc5b4 \uc11c\ub958\ub97c \uc791\uc131\ud574\uc57c \ud569\ub2c8\ub2e4. \uc720\ub7fd\uc758 \uc784\uc0c1\uc2dc\ud5d8 \uc815\ubcf4 \uc2dc\uc2a4\ud15c(CTIS) \ub610\ud55c \ub370\uc774\ud130 \uc138\ubd84\ud654 \ubc0f \uacf5\uac1c \uc758\ubb34\uc5d0 \uc0c1\ub2f9\ud55c \ubcc0\ud654\ub97c \uac00\uc838\uc624\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc5c5\ub370\uc774\ud2b8\ub294 \uc11c\ub85c \ub2e4\ub978 \uad00\ud560\uad8c\uc758 \uae30\ub300\ub97c \ucda9\uc871\uc2dc\ud0ac \uc218 \uc788\ub294 \uc804\ubb38 \uc791\uac00\uc5d0 \ub300\ud55c \uc758\uc874\ub3c4\ub97c \ub192\uc774\uba70, \ub2e8\uae30\uc801\uc73c\ub85c \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5\uc744 \uacac\uc778\ud569\ub2c8\ub2e4.<\/p>\n<p>*   \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ubc0f \ub9de\ucda4\ud615 \uc758\ud559 \ucc44\ud0dd \uc99d\uac00 (+1.9% CAGR \uc601\ud5a5): \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ud3c9\uac00 \ubc0f \uc5f0\uad6c \uc13c\ud130(CBER)\ub294 2025\ub144\uc5d0 \uc720\uc804\uc790 \ubc0f \uc138\ud3ec \uce58\ub8cc\uc81c\uc5d0 \ub300\ud55c \uc9c0\uce68\uc744 \ud655\ub300\ud558\uc5ec \uc804\ud1b5\uc801\uc778 \uc800\ubd84\uc790 \uc758\uc57d\ud488 \uae30\uc900\uc744 \ucd08\uacfc\ud558\ub294 \ub370\uc774\ud130 \uae30\ub300\ub97c \uc81c\uc2dc\ud588\uc2b5\ub2c8\ub2e4. \ub9de\ucda4\ud615 \uc758\ud559 \ud30c\uc774\ud504\ub77c\uc778\uc740 \ubc14\uc774\uc624\ub9c8\ucee4\ubcc4\ub85c \ucc38\uac00\uc790\ub97c \uacc4\uce35\ud654\ud558\uace0 \uc2e4\uc81c \uc99d\uac70\ub97c \ud1b5\ud569\ud558\ub294 \uc801\uc751\ud615 \uc784\uc0c1\uc2dc\ud5d8 \ud504\ub85c\ud1a0\ucf5c\uc744 \uc694\uad6c\ud558\uc5ec \ud398\uc774\uc9c0 \uc218 \uc99d\uac00\uc640 \ubc18\ubcf5\uc801\uc778 \uc5c5\ub370\uc774\ud2b8\ub97c \uc720\ubc1c\ud569\ub2c8\ub2e4. \ubc14\uc774\uc624\uc2dc\ubc00\ub7ec \uac1c\ubc1c\uc790\ub4e4\uc740 \uc0c1\ud638 \uad50\ud658\uc131 \ubc0f \uc81c\uc870 \ubcc0\uacbd \uc0ac\ud56d\uc744 \ub2e4\ub8e8\ub294 \ube44\uad50 \uc11c\uc220\uc744 \uc0dd\uc131\ud574\uc57c \ud558\uba70, \uc774\ub294 \uc81c\ud488 \uc218\uba85 \uc8fc\uae30 \uc804\ubc18\uc5d0 \uac78\uccd0 \ubc18\ubcf5\uc801\uc778 \ubb38\uc11c\ud654 \uc694\uad6c\ub97c \ubc1c\uc0dd\uc2dc\ud0b5\ub2c8\ub2e4. \uc7ac\uc0dd \uc758\ud559 \ucca8\ub2e8 \uce58\ub8cc(RMAT) \uc9c0\uc815\uacfc \uac19\uc740 \uc2e0\uc18d \uacbd\ub85c(Expedited pathways)\ub294 \uac80\ud1a0 \uae30\uac04\uc744 \ub2e8\ucd95\uc2dc\ucf1c \uc791\uac00\ub4e4\uc774 \uac00\uc18d\ud654\ub41c \uc77c\uc815\uc73c\ub85c \ud3ec\uad04\uc801\uc778 \uc11c\ub958\ub97c \uc81c\ucd9c\ud558\ub3c4\ub85d \uc758\ubb34\ud654\ud569\ub2c8\ub2e4.<\/p>\n<p> 3.2. \uc2dc\uc7a5 \uc131\uc7a5 \uc800\ud574 \uc694\uc778<\/p>\n<p>*   \uc219\ub828\ub41c \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc804\ubb38\uac00 \ubd80\uc871 (-1.6% CAGR \uc601\ud5a5): 2024\ub144 \uc0dd\uba85 \uacfc\ud559 \uae30\uc5c5\uc758 83%\uac00 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc9c1\ubb34\ub97c \ucc44\uc6b0\ub294 \ub370 \uc5b4\ub824\uc6c0\uc744 \uacaa\uc5c8\uc73c\uba70, 2030\ub144\uae4c\uc9c0 35%\uc758 \uc778\ub825 \ubd80\uc871\uc774 \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc2a4\ud3f0\uc11c\ub4e4\uc774 \ubcf5\uc7a1\ud55c \uc81c\ud488\uc744 \uad00\ub9ac\ud560 \uc218 \uc788\ub294 \uc120\uc784 \uc791\uac00\ub97c \ud655\ubcf4\ud558\uae30 \uc704\ud574 \uacbd\uc7c1\ud558\uba74\uc11c \uc784\uae08 \uc778\ud50c\ub808\uc774\uc158\uacfc \ud504\ub85c\uc81d\ud2b8 \uc9c0\uc5f0\uc774 \ud754\ud558\uac8c \ubc1c\uc0dd\ud569\ub2c8\ub2e4. \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \uae09\uc18d\ud55c \ubc14\uc774\uc624 \uc81c\uc57d \uc0b0\uc5c5 \ud655\uc7a5\uc73c\ub85c \uc778\ud574 \ud604\uc9c0 \uad50\uc721 \uc5ed\ub7c9\uc744 \ucd08\uacfc\ud558\ub294 \uc778\ub825 \ubd80\uc871\uc5d0 \uc9c1\uba74\ud574 \uc788\uc73c\uba70, \uc774\ub294 \ub192\uc740 \ud574\uc678 \uc778\ub825 \ube44\uc6a9 \ub610\ub294 \ub354 \uae34 \ud504\ub85c\uc81d\ud2b8 \uae30\uac04\uc73c\ub85c \uc774\uc5b4\uc9d1\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc778\ub825 \ubd80\uc871\uc740 \ud504\ub85c\uc81d\ud2b8 \ucc98\ub9ac\ub7c9\uc744 \ub2a6\ucd94\uace0 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5\uc758 \uc131\uc7a5\uc744 \uc5b5\uc81c\ud569\ub2c8\ub2e4.<\/p>\n<p>*   \uc870\ub2ec \ud1b5\ud569\uc73c\ub85c \uc778\ud55c \uac00\uaca9 \uc555\ub825 (-0.9% CAGR \uc601\ud5a5): \ub300\ud615 \uc81c\uc57d \ud68c\uc0ac\ub4e4\uc740 \ub300\ub7c9 \ud560\uc778\uc744 \uc5bb\uae30 \uc704\ud574 \uacf5\uae09\uc5c5\uccb4 \uad00\ub9ac\ub97c \uc911\uc559 \uc9d1\uc911\ud654\ud558\uace0 \uc788\uc73c\uba70, \uc774\ub294 \uc804\ubb38 \ubb38\uc11c \uc791\uc131 \ubd80\ud2f0\ud06c\uc758 \ub9c8\uc9c4\uc744 \uc555\ubc15\ud569\ub2c8\ub2e4. \ud45c\uc900\ud654\ub41c \uc694\uc728\ud45c\uc640 \uae34 \uc870\ub2ec \uc8fc\uae30\ub294 \uc11c\ube44\uc2a4\ub97c \ubb36\uc744 \uc218 \uc788\ub294 \ud1b5\ud569 CRO\uc5d0 \uc720\ub9ac\ud558\uac8c \uc791\uc6a9\ud558\uc5ec \uc18c\uaddc\ubaa8 \uae30\uc5c5\uc758 \ud611\uc0c1\ub825\uc744 \uc57d\ud654\uc2dc\ud0b5\ub2c8\ub2e4. \uc778\ud50c\ub808\uc774\uc158\uc73c\ub85c \uc778\ud55c \uc6b4\uc601 \ube44\uc6a9\uc740 \ub9c8\uc9c4 \uc555\ub825\uc744 \uc2ec\ud654\uc2dc\ucf1c \uacf5\uae09\uc5c5\uccb4\ub4e4\uc774 \uc77c\uc0c1\uc801\uc778 \uc791\uc5c5\uc744 \uc790\ub3d9\ud654\ud558\uace0 \uace0\ubd80\uac00\uac00\uce58 \ud2c8\uc0c8 \uc11c\ube44\uc2a4\uc5d0 \uc9d1\uc911\ud558\ub3c4\ub85d \uac15\uc694\ud569\ub2c8\ub2e4. \uc77c\ubc18 \ubb38\uc11c\uc5d0 \ub300\ud55c \uacbd\uc7c1 \uc785\ucc30\uc740 \uc0c1\ud488\ud654\ub97c \uc720\ub3c4\ud558\uc9c0\ub9cc, \uc2ec\uce35\uc801\uc778 \uc804\ubb38 \uc9c0\uc2dd\uc774 \ud544\uc694\ud55c \ucca8\ub2e8 \uce58\ub8cc\uc81c \uc11c\ub958\uc5d0\ub294 \ud504\ub9ac\ubbf8\uc5c4 \uac00\uaca9\uc774 \uc720\uc9c0\ub429\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc774\ubd84\ubc95\uc740 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5 \ub0b4 \uc804\ubc18\uc801\uc778 \ub9e4\ucd9c \uc99d\uac00\ub97c \uc81c\ud55c\ud569\ub2c8\ub2e4.<\/p>\n<p># 4. \uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d<\/p>\n<p> 4.1. \uc720\ud615\ubcc4: \uaddc\uc81c \uc804\ubb38\uc131\uc774 \ud504\ub9ac\ubbf8\uc5c4 \ud3ec\uc9c0\uc154\ub2dd\uc744 \uc8fc\ub3c4<\/p>\n<p>*   \uaddc\uc81c \uc758\ub8cc \ubb38\uc11c \uc791\uc131(Regulatory Medical Writing): 2025\ub144 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 41.88%\ub97c \ucc28\uc9c0\ud558\uba70, \uc99d\uac00\ud558\ub294 \uc9c0\uce68 \ubb38\uc11c \uc18d\uc5d0\uc11c \uaddc\uc81c \uc900\uc218 \uc911\uc2ec\uc758 \uacb0\uacfc\ubb3c\uc5d0 \ub300\ud55c \ud504\ub9ac\ubbf8\uc5c4\uc744 \uac15\uc870\ud569\ub2c8\ub2e4.<br \/>\n*   \uacfc\ud559 \ubc0f HEOR \ubb38\uc11c \uc791\uc131(Scientific and HEOR Writing): 2031\ub144\uae4c\uc9c0 10.74%\uc758 \uac00\uc7a5 \ube60\ub978 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \uc9c0\ubd88\uc790\ub4e4\uc774 \uaddc\uc81c \uc81c\ucd9c\uacfc \ud568\uaed8 \uc2e4\uc81c \uc99d\uac70 \ubc0f \uac74\uac15 \uacbd\uc81c\uc801 \uc815\ub2f9\ud654\ub97c \uc694\uad6c\ud568\uc5d0 \ub530\ub77c \uc131\uc7a5\ud569\ub2c8\ub2e4.<br \/>\n*   \uc784\uc0c1 \ubb38\uc11c \uc791\uc131(Clinical Writing): \uc9c0\uc5ed \uc5b8\uc5b4 \ubc0f \uac1c\uc778 \uc815\ubcf4 \ubcf4\ud638 \uaddc\uc815\uc744 \ucda9\uc871\ud574\uc57c \ud558\ub294 \ubd84\uc0b0\ud615 \ud504\ub85c\ud1a0\ucf5c\uc744 \uc9c0\uc6d0\ud558\uba70 \uafb8\uc900\ud55c \uc218\uc694\ub97c \ubcf4\uc785\ub2c8\ub2e4.<br \/>\n*   \uc2e0\ud765 \uce74\ud14c\uace0\ub9ac: \ub514\uc9c0\ud138 \uac74\uac15 \uae30\uc220\uc744 \uc704\ud55c AI \uc9c0\uc6d0 \uc791\uc131 \uc9c0\uc6d0\uc744 \ud3ec\ud568\ud558\uba70, \uacf5\uae09\uc5c5\uccb4\ub4e4\uc774 \ubcc0\ud654\ud558\ub294 \uace0\uac1d \uc694\uad6c\ub97c \ucda9\uc871\ud558\uae30 \uc704\ud574 \ud3ec\ud2b8\ud3f4\ub9ac\uc624\ub97c \ub2e4\uac01\ud654\ud558\ub294 \ubc29\uc2dd\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4.<\/p>\n<p> 4.2. \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: \ubc14\uc774\uc624\ud14d \ud601\uc2e0\uc774 \uc544\uc6c3\uc18c\uc2f1 \uac00\uc18d\ud654\ub97c \uc8fc\ub3c4<\/p>\n<p>*   \uc81c\uc57d \ud68c\uc0ac(Pharmaceutical Companies): 2025\ub144 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5 \uaddc\ubaa8\uc758 49.20%\ub97c \ucc28\uc9c0\ud558\uba70, \uc9c0\uc18d\uc801\uc778 \uae00\ub85c\ubc8c \uc11c\ub958 \uc5c5\ub370\uc774\ud2b8\uac00 \ud544\uc694\ud55c \ub300\uaddc\ubaa8 \ud30c\uc774\ud504\ub77c\uc778\uc5d0 \uc758\ud574 \uc720\uc9c0\ub429\ub2c8\ub2e4.<br \/>\n*   \uc0dd\uba85\uacf5\ud559 \ud68c\uc0ac(Biotechnology Companies): 2031\ub144\uae4c\uc9c0 10.6%\uc758 CAGR\ub85c \ud655\uc7a5\ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \ud575\uc2ec R&#038;D \ud65c\ub3d9\uc5d0 \uc9d1\uc911\ud558\uae30 \uc704\ud574 \uac70\uc758 \ubaa8\ub4e0 \ubb38\uc11c\ud654 \uc791\uc5c5\uc744 \uc544\uc6c3\uc18c\uc2f1\ud558\ub294 \uacbd\ud5a5\uc774 \uc788\uc2b5\ub2c8\ub2e4. \uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c\ub97c \uac1c\ubc1c\ud558\ub294 \ubc14\uc774\uc624\ud14d \uc2a4\ud3f0\uc11c\ub4e4\uc740 \ub0b4\ubd80 \uc5ed\ub7c9\uc744 \ucd08\uacfc\ud558\ub294 \ucca8\ub2e8 CMC \uc139\uc158 \ubc0f \uc704\ud5d8-\uc774\uc810 \ubd84\uc11d\uc744 \uc544\uc6c3\uc18c\uc2f1\ud558\uc5ec \uc804\ubc18\uc801\uc778 \uc2dc\uc7a5 \uc131\uc7a5\uc744 \ucd09\uc9c4\ud569\ub2c8\ub2e4.<br \/>\n*   \uae30\ud0c0: CRO \ubc0f \uc804\ubb38 \uae30\uc5c5\ub4e4\uc740 \uc2a4\ud3f0\uc11c \ud300 \ub0b4\uc5d0 \uc791\uac00\ub97c \ubc30\uce58\ud558\uc5ec \uc9c0\uc2dd \ubcf4\uc874 \ubc0f \uc6b4\uc601 \ubbfc\ucca9\uc131\uc744 \ud5a5\uc0c1\uc2dc\ud0b4\uc73c\ub85c\uc368 \uc7a5\uae30\uc801\uc778 \ud30c\ud2b8\ub108\ub85c \uc790\ub9ac\ub9e4\uae40\ud569\ub2c8\ub2e4. \uc758\ub8cc \uae30\uae30 \uc81c\uc870\uc5c5\uccb4 \ubc0f \ud559\uc220 \uae30\uad00\uc740 \uc18c\ubd84\uc790 \uc790\uae08 \uc870\ub2ec \uc8fc\uae30 \ub3d9\uc548 \ub9e4\ucd9c\uc744 \uc548\uc815\ud654\ud558\ub294 \ubcf4\uc870 \uc218\uc694 \ud480\uc744 \ud615\uc131\ud569\ub2c8\ub2e4.<\/p>\n<p> 4.3. \uce58\ub8cc \uc601\uc5ed\ubcc4: \uc885\uc591\ud559 \ub9ac\ub354\uc2ed, \uba74\uc5ed\ud559\uc758 \ub3c4\uc804 \uc9c1\uba74<\/p>\n<p>*   \uc885\uc591\ud559(Oncology): 2025\ub144 \ub9e4\ucd9c\uc758 36.18%\ub85c \uac00\uc7a5 \ud070 \ube44\uc911\uc744 \ucc28\uc9c0\ud588\uc73c\uba70, FDA\uc758 \uac04\uc18c\ud654\ub41c \uc870\uc9c1-\ubd88\uac00\uc9c0\ub860\uc801 \uc2b9\uc778 \uacbd\ub85c\uc640 \uc815\uad50\ud55c \uc5d4\ub4dc\ud3ec\uc778\ud2b8 \uc11c\uc220\uc774 \ud544\uc694\ud55c \uae30\ub85d\uc801\uc778 \uc218\uc758 2\/3\uc0c1 \uc885\uc591\ud559 \uc784\uc0c1\uc2dc\ud5d8\uc5d0 \uc758\ud574 \uc9c0\uc6d0\ub429\ub2c8\ub2e4.<br \/>\n*   \uba74\uc5ed\ud559(Immunology): \uc720\uc804\uc790 \ud3b8\uc9d1 \uce58\ub8cc\uc81c \ubc0f \uc790\uac00\uba74\uc5ed \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\uac00 \uc11c\ub958 \ubcf5\uc7a1\uc131\uc744 \uc99d\ud3ed\uc2dc\ud0a4\uba74\uc11c 10.77%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uae30\ud0c0: CNS(\uc911\ucd94\uc2e0\uacbd\uacc4) \ubc0f \ud76c\uadc0 \uc9c8\ud658 \ud3ec\ud2b8\ud3f4\ub9ac\uc624\uc5d0\uc11c \uc99d\uac00\ud558\ub294 \ubb38\uc11c\ud654 \uc694\uad6c \uc0ac\ud56d(\uc801\uc751\ud615 \uc124\uacc4 \ubc0f \ub300\ub9ac \uc5d4\ub4dc\ud3ec\uc778\ud2b8 \ud3ec\ud568) \ub610\ud55c \uc2dc\uc7a5 \uc131\uc7a5\uc5d0 \uae30\uc5ec\ud569\ub2c8\ub2e4. \uce58\ub8cc \uc601\uc5ed\uc758 \ub2e4\uac01\ud654\ub294 \uc791\uac00\ub4e4\uc774 \ubc14\uc774\uc624\ub9c8\ucee4 \uc804\ub7b5, \ud658\uc790 \ubcf4\uace0 \uacb0\uacfc \ubc0f \uaddc\uc81c \uacfc\ud559\uc744 \ud1b5\ud569\ud558\ub294 \ub2e4\ud559\uc81c\uc801 \uc804\ubb38 \uc9c0\uc2dd\uc744 \ud568\uc591\ud558\ub3c4\ub85d \uc720\ub3c4\ud569\ub2c8\ub2e4.<\/p>\n<p># 5. \uc9c0\uc5ed \ubd84\uc11d<\/p>\n<p>*   \ubd81\ubbf8: 2025\ub144 \ub9e4\ucd9c\uc758 39.75%\ub97c \ucc3d\ucd9c\ud588\uc73c\uba70, 2024\ub144 25\uac1c \uc774\uc0c1\uc758 \uc0c8\ub85c\uc6b4 \uc9c0\uce68 \ubb38\uc11c\ub97c \ubc1c\ud45c\ud558\uc5ec \uc11c\ub958 \uae38\uc774\ub97c \ub298\ub9ac\uace0 \ube60\ub978 \uaddc\uc81c \uc900\uc218 \uc5c5\ub370\uc774\ud2b8\ub97c \uc694\uad6c\ud55c \ubbf8\uad6d\uc5d0 \uc758\ud574 \uc8fc\ub3c4\ub429\ub2c8\ub2e4. \uce90\ub098\ub2e4\uc640 \uba55\uc2dc\ucf54\ub294 \uc81c\ucd9c\uc744 \uac04\uc18c\ud654\ud558\ub294 \uc870\ud654\ub41c \uc774\ub2c8\uc154\ud2f0\ube0c\ub97c \ud1b5\ud574 \ucc38\uc5ec\ud558\uc9c0\ub9cc \uc5ec\uc804\ud788 \ubbf8\uad6d \uc120\ub840\uc5d0 \uc758\uc874\ud558\uc5ec \uc774 \uc9c0\uc5ed\uc758 \ub9ac\ub354\uc2ed\uc744 \uac15\ud654\ud569\ub2c8\ub2e4.<br \/>\n*   \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591: 10.82%\uc758 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, 24\uac1c \uac1c\ud601 \uc870\uce58\ub97c \ucd94\uac00\ud558\uace0 2027\ub144\uae4c\uc9c0 \ud604\uc9c0\ud654\ub41c \uc591\uc2dd\uc744 \uc758\ubb34\ud654\ud558\ub294 \uc911\uad6d\uc758 \ub2e4\ub144\uac04 \uac1c\ud601\uc744 \ubc18\uc601\ud569\ub2c8\ub2e4. \uc77c\ubcf8\uc758 \uace0\uc720 \uc784\uc0c1 \ub370\uc774\ud130 \uc120\ud638\uc640 \uc778\ub3c4\uc758 \uc2e0\uc18d \ucc98\ub9ac \uaddc\uce59\uc740 \ubaa8\ub450 \uae00\ub85c\ubc8c \uc139\uc158\uacfc \uad6d\uac00\ubcc4 \ud45c\uc900\uc744 \uc870\ud654\uc2dc\ud0ac \uc218 \uc788\ub294 \uc804\ubb38 \uc791\uac00\uc5d0 \ub300\ud55c \uc9c0\uc18d\uc801\uc778 \uc218\uc694\ub97c \ucc3d\ucd9c\ud569\ub2c8\ub2e4.<br \/>\n*   \uc720\ub7fd: EMA\uc758 \uc784\uc0c1\uc2dc\ud5d8 \uc815\ubcf4 \uc2dc\uc2a4\ud15c(CTIS)\uc774 \uc2a4\ud3f0\uc11c\ub4e4\uc5d0\uac8c \uc0c8\ub85c\uc6b4 \uacf5\uacf5 \ud22c\uba85\uc131 \uae30\uc900\uc744 \ucda9\uc871\ud558\ub294 \uc870\ud654\ub41c \uc11c\ub958\ub97c \uc81c\ucd9c\ud558\ub3c4\ub85d \uc758\ubb34\ud654\ud568\uc5d0 \ub530\ub77c \uc5ec\uc804\ud788 \uc911\uc694\ud55c \uc9c0\uc5ed\uc785\ub2c8\ub2e4. \ub3c5\uc77c, \ud504\ub791\uc2a4, \uc601\uad6d\uc740 \uae00\ub85c\ubc8c \uc139\uc158\uc744 \ud604\uc9c0 \ub77c\ubca8\ub9c1 \ubc95\uaddc\uc5d0 \uc138\uc2ec\ud558\uac8c \uc801\uc6a9\ud574\uc57c \ud558\ubbc0\ub85c \ubb38\uc11c \uc791\uc131 \uc8fc\uae30\uac00 \uae38\uc5b4\uc9d1\ub2c8\ub2e4.<br \/>\n*   \ub77c\ud2f4 \uc544\uba54\ub9ac\uce74 \ubc0f \uc911\ub3d9 &#038; \uc544\ud504\ub9ac\uce74: ICH \uac00\uc774\ub4dc\ub77c\uc778\uc758 \uafb8\uc900\ud55c \ucc44\ud0dd\uc744 \ubcf4\uc5ec\uc8fc\uba70, \uacf5\uae09\uc5c5\uccb4\ub4e4\uc774 \uc9c0\uc5ed \ud5c8\ube0c\ub97c \ud1b5\ud574 \ubaa9\ud45c\ub85c \ud558\ub294 \ubbf8\ub798 \uc131\uc7a5 \ub178\ub4dc\ub97c \ub098\ud0c0\ub0c5\ub2c8\ub2e4.<\/p>\n<p># 6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<p>\uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5\uc740 \uae00\ub85c\ubc8c CRO\uc640 \ud2c8\uc0c8 \ucee8\uc124\ud305 \ud68c\uc0ac\ub4e4\uc774 \uc810\uc720\uc728\uc744 \ub193\uace0 \uacbd\uc7c1\ud558\ub294 \uc911\uac04 \uc815\ub3c4\uc758 \ud30c\ud3b8\ud654\ub41c \uc2dc\uc7a5\uc785\ub2c8\ub2e4. IQVIA, ICON, Parexel\uacfc \uac19\uc740 \uc120\ub450 \uae30\uc5c5\ub4e4\uc740 \uc784\uc0c1 \uc6b4\uc601, \uaddc\uc81c \uc804\ub7b5 \ubc0f \ubb38\uc11c \uc791\uc131 \uc804\ubb38 \uc9c0\uc2dd\uc744 \uacb0\ud569\ud55c \ud1b5\ud569 \ud50c\ub7ab\ud3fc\uc744 \ud65c\uc6a9\ud558\uc5ec \ub300\uaddc\ubaa8 \ub2e4\uad6d\uc801 \ud504\ub85c\uadf8\ub7a8\uc744 \ud655\ubcf4\ud569\ub2c8\ub2e4. 2024\ub144 3\uc6d4 Indegene\uc5d0 \uc778\uc218\ub41c Trilogy Writing &#038; Consulting\uacfc \uac19\uc740 \uc804\ubb38 \uae30\uc5c5\ub4e4\uc740 \uc2ec\uce35\uc801\uc778 \uce58\ub8cc \uc9c0\uc2dd\uacfc \ubbfc\ucca9\ud55c \uc81c\uacf5 \ubaa8\ub378\uc5d0 \uc911\uc810\uc744 \ub450\uc5b4 \uc911\uacac \uc2a4\ud3f0\uc11c\ub4e4\uc5d0\uac8c \uc5b4\ud544\ud569\ub2c8\ub2e4.<\/p>\n<p>\uae30\uc220\uc740 \uacf5\uae09\uc5c5\uccb4\ub4e4\uc774 \uacfc\ud559\uc801 \ubb34\uacb0\uc131\uc744 \uc704\ud574 \uc778\uac04\uc758 \uac10\ub3c5\uc744 \uc720\uc9c0\ud558\uba74\uc11c \ucd08\uc548 \uc791\uc131 \ubc0f \ubc84\uc804 \uad00\ub9ac\ub97c \uac00\uc18d\ud654\ud558\uae30 \uc704\ud574 \ud1b5\uc81c\ub41c \uc0dd\uc131\ud615 AI \uc5d4\uc9c4\uc744 \ubc30\ud3ec\ud568\uc5d0 \ub530\ub77c \uc911\uc694\ud55c \ucc28\ubcc4\ud654 \uc694\uc18c\ub85c \ub0a8\uc544 \uc788\uc2b5\ub2c8\ub2e4. Indegene\uc758 \uc778\uc218 \ud6c4 \ub3c5\uc810 AI \uc9c0\uc6d0 \ud50c\ub7ab\ud3fc \ucd9c\uc2dc\ub294 \uaddc\uc81c \uc900\uc218\ub97c \uc190\uc0c1\uc2dc\ud0a4\uc9c0 \uc54a\uc73c\uba74\uc11c \uc8fc\uae30 \uc2dc\uac04\uc744 \ucd5c\ub300 25% \ub2e8\ucd95\ud560 \uac83\uc744 \uc57d\uc18d\ud569\ub2c8\ub2e4. eCTD \uacf5\uae09\uc5c5\uccb4 \ubc0f \ubc88\uc5ed \ud68c\uc0ac\uc640\uc758 \uc804\ub7b5\uc801 \ud30c\ud2b8\ub108\uc2ed\uc740 \ucd09\ubc15\ud55c \uae30\ud55c \ub0b4\uc5d0 \uae00\ub85c\ubc8c \uc81c\ucd9c\uc744 \ucd94\uad6c\ud558\ub294 \uc2a4\ud3f0\uc11c\ub4e4\uc5d0\uac8c \uc6d0\uc2a4\ud1b1 \uc194\ub8e8\uc158\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc120\uc784 \uc791\uac00 \ubd80\uc871\uc774 \uc81c\uacf5 \uc5ed\ub7c9\uc5d0 \uc601\ud5a5\uc744 \ubbf8\uce58\uae30 \ub54c\ubb38\uc5d0 \uc778\uc7ac \ud655\ubcf4\ub294 \uc911\uc694\ud55c \uacbd\uc7c1 \uc6b0\uc704 \uc694\uc18c\uc785\ub2c8\ub2e4. \uae30\uc5c5\ub4e4\uc740 \uaddc\uc81c \uc720\ucc3d\uc131\uacfc \uce58\ub8cc \uae4a\uc774\ub97c \ud568\uc591\ud558\uae30 \uc704\ud574 \uae00\ub85c\ubc8c \uad50\uc721 \uc544\uce74\ub370\ubbf8 \ubc0f \uba58\ud1a0\ub9c1 \ud504\ub85c\uadf8\ub7a8\uc5d0 \ud22c\uc790\ud569\ub2c8\ub2e4. \uc219\ub828\ub41c \ud300\uc744 \ud655\ubcf4\ud558\uba74\uc11c \ube44\uc6a9 \uacbd\uc7c1\ub825\uc744 \uc720\uc9c0\ud560 \uc218 \uc788\ub294 \uacf5\uae09\uc5c5\uccb4\ub294 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5\uc5d0\uc11c \uc810\uc720\uc728\uc744 \ub192\uc77c \uc900\ube44\uac00 \ub418\uc5b4 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uc2dc\uc7a5 \ucc38\uc5ec\uc790:<br \/>\n*   Paraxel International<br \/>\n*   IQVIA Inc<br \/>\n*   Laboratory Corporation of America Holdings<br \/>\n*   Icon Plc<br \/>\n*   Cardinal Health<\/p>\n<p># 7. \ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5<\/p>\n<p>*   2024\ub144 9\uc6d4: Freyr Solutions\ub294 \uc758\ub8cc \uae30\uae30 \uac1c\ubc1c\uc744 \uc704\ud55c \ud3ec\uad04\uc801\uc778 \uc778\uc801 \uc694\uc18c \uacf5\ud559(Human Factors Engineering) \uc11c\ube44\uc2a4\ub97c \ucd9c\uc2dc\ud558\uc5ec \uae30\uae30 \uc0ac\uc6a9\uc131 \uaddc\uc81c \uc900\uc218\ub97c \uc704\ud55c \uaddc\uc81c \ucee8\uc124\ud305 \uc5ed\ub7c9\uc744 \ud655\uc7a5\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2024\ub144 7\uc6d4: Allucent\ub294 BARDA\uc640 5\ub144 \uacc4\uc57d\uc744 \uccb4\uacb0\ud558\uc5ec \uc758\ub8cc \ub300\ucc45 \uc5f0\uad6c\ub97c \uc704\ud55c \ubd84\uc0b0\ud615 \uc784\uc0c1\uc2dc\ud5d8 \uc5ed\ub7c9\uc744 \uac15\ud654\ud558\uace0 \ud658\uc790 \uc911\uc2ec \uc6b4\uc601 \ubaa8\ub378\uc744 \uac15\ud654\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2024\ub144 6\uc6d4: ClinicalMind\ub294 Sensified\ub97c \uc778\uc218\ud558\uc5ec KOL(Key Opinion Leader) \ucc38\uc5ec \ubc0f \ub514\uc9c0\ud138 \uac74\uac15 \uae30\uc220 \uc9c0\uc6d0\uc744 \uac15\ud654\ud558\ub294 \ud1b5\ud569 \uc758\ub8cc \ucee4\ubba4\ub2c8\ucf00\uc774\uc158 \ubc0f \uad50\uc721 \ud50c\ub7ab\ud3fc\uc744 \uad6c\ucd95\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2024\ub144 3\uc6d4: Indegene\uc740 Trilogy Writing &#038; Consulting GmbH \uc778\uc218\ub97c \uc644\ub8cc\ud558\uc5ec 22\ub144\uac04\uc758 \uaddc\uc81c \ubb38\uc11c \uc791\uc131 \uc804\ubb38 \uc9c0\uc2dd\uacfc AI \uae30\ubc18 \uc0dd\uc0b0\uc131 \ub3c4\uad6c\ub97c \ud1b5\ud569\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc758\ub8cc \ubb38\uc11c \uc791\uc131(Medical Writing) \uc2dc\uc7a5 \ubcf4\uace0\uc11c \uc694\uc57d<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc758\ub8cc \uc804\ubb38\uac00\uac00 \ucd9c\ud310 \ubc0f \uaddc\uc81c \uc81c\ucd9c\uc744 \uc704\ud574 \uacfc\ud559 \ubb38\uc11c\ub97c \uc791\uc131\ud558\ub294 \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5\uc5d0 \ub300\ud55c \ud3ec\uad04\uc801\uc778 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \uc2dc\uc7a5\uc740 \uc720\ud615(\uaddc\uc81c, \uc784\uc0c1, \uacfc\ud559 \ubc0f HEOR \ub4f1), \ucd5c\uc885 \uc0ac\uc6a9\uc790(\uc81c\uc57d \ud68c\uc0ac, \uc0dd\uba85\uacf5\ud559 \ud68c\uc0ac, \uacc4\uc57d \uc5f0\uad6c \uae30\uad00(CRO), \uc758\ub8cc \uae30\uae30 \uc81c\uc870\uc5c5\uccb4, \ud559\uc220 \ubc0f \uc5f0\uad6c \uae30\uad00 \ub4f1), \uce58\ub8cc \uc601\uc5ed(\uc885\uc591\ud559, \uc2ec\uc7a5\ud559, \uc911\ucd94\uc2e0\uacbd\uacc4 \ubc0f \uc2e0\uacbd\ud559, \uba74\uc5ed\ud559, \ud76c\uadc0 \uc9c8\ud658 \ub4f1), \uadf8\ub9ac\uace0 \uc9c0\uc5ed(\ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8)\ubcc4\ub85c \uc138\ubd84\ud654\ub418\uc5b4 \uc788\uc2b5\ub2c8\ub2e4. \ud2b9\ud788 17\uac1c \uc8fc\uc694 \uad6d\uac00\uc5d0 \ub300\ud55c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \ub3d9\ud5a5 \ucd94\uc815\uce58\ub97c \ud3ec\ud568\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc2dc\uc7a5\uc740 2026\ub144 43\uc5b5 3\ucc9c\ub9cc \ub2ec\ub7ec\uc5d0\uc11c 2031\ub144 69\uc5b5 7\ucc9c\ub9cc \ub2ec\ub7ec \uaddc\ubaa8\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc774 \uc911 \uacfc\ud559 \ubc0f HEOR(Health Economics and Outcomes Research) \ubb38\uc11c \uc791\uc131 \ubd80\ubb38\uc740 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 10.74%\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\ub294\ub370, \uc774\ub294 \uc2a4\ud3f0\uc11c\ub4e4\uc774 \uc2e4\uc81c \uc99d\uac70(real-world evidence)\uc640 \uc9c0\ubd88\uc790 \uc911\uc2ec \ubd84\uc11d(payer-focused analyses)\uc744 \ucd94\uad6c\ud558\uae30 \ub54c\ubb38\uc785\ub2c8\ub2e4. \uc9c0\uc5ed\ubcc4\ub85c\ub294 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc774 \uc911\uad6d\uc758 \uaddc\uc81c \uac1c\ud601\uacfc \ubd84\uc0b0\ud615 \uc784\uc0c1\uc2dc\ud5d8(decentralized trials)\uc758 \ud655\uc0b0\uc73c\ub85c \uc778\ud574 \ub2e4\uad6d\uc5b4 \ud504\ub85c\ud1a0\ucf5c \uac1c\ubc1c \ubc0f \ud604\uc9c0 \uc81c\ucd9c \uc804\ubb38\uc131\uc5d0 \ub300\ud55c \uc218\uc694\uac00 \uc99d\uac00\ud558\uba74\uc11c 10.82%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub978 \uc131\uc7a5\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5\uc758 \uc8fc\uc694 \uc131\uc7a5 \ub3d9\ub825\uc73c\ub85c\ub294 \uc5f0\uad6c \uac1c\ubc1c(R&#038;D) \uc9c0\ucd9c \uc99d\uac00 \ubc0f \uc2e0\uaddc \uce58\ub8cc\uc81c \uac1c\ubc1c, CRO \uc544\uc6c3\uc18c\uc2f1 \ubaa8\ub378\uc758 \ud655\uc7a5, \uaddc\uc81c \ubcf5\uc7a1\uc131 \ubc0f \ubb38\uc11c\ub7c9 \uc99d\uac00, \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ubc0f \ub9de\ucda4\ud615 \uc758\ud559\uc758 \ucc44\ud0dd \uc99d\uac00, \uc804\ubb38\uac00 \uac10\ub3c5\uc774 \ud544\uc694\ud55c AI \uae30\ubc18 \ucf58\ud150\uce20 \uc790\ub3d9\ud654, \uadf8\ub9ac\uace0 \uc801\uc751\ud615 \ub2e4\uad6d\uc5b4 \ud504\ub85c\ud1a0\ucf5c\uc744 \uc694\uad6c\ud558\ub294 \ubd84\uc0b0\ud615\/\uac00\uc0c1 \uc784\uc0c1\uc2dc\ud5d8\uc758 \ud655\uc0b0 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubc18\uba74, \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c\ub294 \uc219\ub828\ub41c \uc758\ub8cc \ubb38\uc11c \uc791\uc131 \uc804\ubb38\uac00\uc758 \ubd80\uc871, \uc870\ub2ec \ud1b5\ud569\uc73c\ub85c \uc778\ud55c \uac00\uaca9 \uc555\ubc15, \uc720\ub839 \uc800\uc791(ghost-writing) \ubc0f \uc800\uc790 \ud22c\uba85\uc131\uc5d0 \ub300\ud55c \uaddc\uc81c \uc2ec\uc0ac \uac15\ud654, \uadf8\ub9ac\uace0 \uc9c0\uc5ed\ubcc4 \uc81c\ucd9c \ud15c\ud50c\ub9bf\uc5d0 \ub300\ud55c \ub192\uc740 \uaddc\uc81c \uc900\uc218 \ube44\uc6a9 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc778\uacf5\uc9c0\ub2a5(AI)\uc740 \ucd08\uae30 \ucd08\uc548 \uc791\uc131 \ubc0f \ub370\uc774\ud130 \ud14c\uc774\ube14 \uc0dd\uc131 \uc18d\ub3c4\ub97c \ub192\uc774\ub294 \ub370 \uae30\uc5ec\ud558\uc9c0\ub9cc, \uaddc\uc81c \ub2f9\uad6d\uc740 \uc5ec\uc804\ud788 \uc778\uac04\uc758 \uac10\ub3c5\uc744 \uc694\uad6c\ud558\uace0 \uc788\uc5b4 \ud488\uc9c8 \uac70\ubc84\ub10c\uc2a4\uc5d0 \ub2a5\uc219\ud55c \uc120\uc784 \uc791\uac00\uc5d0 \ub300\ud55c \uc218\uc694\ub97c \uc99d\uac00\uc2dc\ud0a4\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf4\uace0\uc11c\ub294 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4, \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d, \uc8fc\uc694 \uae30\uc5c5(IQVIA Inc., ICON plc, LabCorp, Parexel International \ub4f1)\uc758 \ud504\ub85c\ud544\uc744 \ud3ec\ud568\ud55c \uacbd\uc7c1 \ud658\uacbd\uc744 \uc0c1\uc138\ud788 \ub2e4\ub8f9\ub2c8\ub2e4. \ub610\ud55c, \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd \uc139\uc158\uc5d0\uc11c\ub294 \ubbf8\uac1c\ucc99 \uc601\uc5ed(white-space) \ubc0f \ubbf8\ucda9\uc871 \uc218\uc694(unmet-need)\uc5d0 \ub300\ud55c \ud3c9\uac00\ub97c \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-32769","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/32769"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=32769"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/32769\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=32769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=32769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=32769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}